Today was my first full day clinic where not a single patient was receiving chemotherapy - everyone was on targeted therapy or immunotherapy. Slow but steady progress in cancer care
Sandip Patel MD FASCO
6,607 posts
Sandip Patel MD FASCO
@PatelOncology
Professor, Medical Oncology @UCSD; Phase 1 & thoracic/NSCLC immunotherapy, solid tumor cell therapy, irAEs, wearables, cancer informatics & AI
- Pfizer/BT data from Nature. Pilot arm got 60ug as single dose (2x approved dose). Minimal T cell responses without boost. UK is playing with fire (half of this dose x1). Short term thinking got us into this mess, won’t help us get out of it either.May end up breeding resistance
- Never let anyone tell you that 4mo PFS is not significant...
- Appreciative of the support and grateful for the promotion to clinical Professor from @UCSDCancer @ucsdim @UCSDHealth
- My favorite oncology ICD10 code is D49.9 “Neoplasm of unspecific behavior of unspecific site”. Code might as well have been an emoji ¯\_(ツ)_/¯
- Replying to @florian_krammerAgree what U.K. doing with single dose is extraordinarily dangerous in either leading to shorter term immunity (“best” case) or breeding resistance (“worse” case). What are we going to name the new resistant COVID19 variant that emerges from the UK’s flawed policy anyway?
- Thanks to @NCIDirector @NCICTEP_ClinRes @SWOG for this award and support of our study S1609 evaluating immune checkpoint blockade across rare cancers @EladSharonMD @Dr_R_Kurzrock @youngkwangchae @UCSDCancer
- Our @nature paper (nature.com/articles/s4158…) is out led by our (+@KnightLabNews) amazing MD/PhD student @multi_omics suggesting a liquid biopsy microbiome approach to detection of early cancers. @ucsd @CMIdigest @JenyaKopylova @CMI_Austin @DrRanaMcKay @sandrinemiller @sejsong
- Shoutout to all the GI med onc nurses, admins, and docs out there taking phone calls and messages from patients about the MSI-H neoadjuvant data from ASCO with dostarlimab. Great trial result, but sensationalistic media headlines are a disservice
- One major indirect benefit of following your patients on hospice is you get a sense of the true burden of their treatment when we see how much better they feel off of it. A lot of toxicities are not readily quantifiable and are only really seen when the treatment is stopped
- Grateful to @asco for a wonderful year of learning and friendship as part of the ASCO Leadership Development Program!
- The irony of walking outside on the McCormick North/South bridge from the ASCO lung cancer session trying to dodge second hand smoke is a bit much to bear. Smoking here should be banned (Also we have children here on site now). @ASCO @OncoAlert
- Why do we need like 5 versions of our CVs for academic medicine again (generic long CV, abbreviated CV, university promotions CV, NIH biosketch, DOD). We really can’t just have a single one one containing all the necessary elements?
- One key point in using sotarasib is that PPI or H2 reduces sotorasib Cmax by 65% and AUC by 57%. This is a major reduction with unknown consequences. For me, I am holding PPI and H2 if giving sotorasib and relying on tums etc 4hrs before (or 10hrs after) taking sotarasib